为什么要与澳门在线赌城娱乐合作?

We have a global strength, with balanced presence across regions and disease areas. 澳门第一赌城在线娱乐的创新药物, many of which are developed in partnership with others, are used by millions of patients worldwide.

首页 / 合作 /为什么与澳门在线赌城娱乐合作

$37.4bn

总营收

$876m

合作的收入

>75

major or strategically important business development transactions completed in last three years

>1,000

collaborations worldwide help us access the best science, stimulate innovation and accelerate delivery of new medicines for unmet medical needs

83,100

员工

28

manufacturing sites in 16 countries

$9.7bn

投资于澳门第一赌城在线娱乐的科学

90%

of pipeline incorporates a precision medicine approach


For year ending 31 December 2021
 

Pushing the boundaries of science to deliver life-changing medicines

Inspired by our values and what science can do, we are focused on accelerating the delivery of life-changing medicines that create enduring value for patients and society.
科学的功能

Our range of scientific capabilities spans biologics and small molecules, 以及新的药物模式. We are looking for new and emerging drug platforms that can revolutionise the treatment of diseases. Examples are in vivo expressed biologics, 新型双特异性抗体, and nanobots/smart drug-delivery systems.

基因组学和数据科学

We are also harnessing the growing potential of genomic and data science to increase our understanding of disease at the molecular level. This is opening the way to pursuing the next wave of disruptive R&D platforms with new scientific modalities such as PROTACs and cell therapies; new technologies, such as 'omics'; and new biology, 比如表观遗传学, oligonucleotides and antibody drug conjugates.

Encouraging innovation and inspiring the next generation of start-ups

Entrepreneurial thinking is one of our core values and at the heart of what we do. We are also passionate about supporting innovation in life sciences and helping the next generation of entrepreneurs succeed within our local bioscience ecosystems globally. 

澳门在线赌城娱乐

Veeva ID: Z4-49876
Date of preparation: November 2022